A nuclear export signal within the structural Gag protein is required for prototype foamy virus replication. 2011

Noémie Renault, and Joelle Tobaly-Tapiero, and Joris Paris, and Marie-Lou Giron, and Audrey Coiffic, and Philippe Roingeard, and Ali Saïb
CNRS UMR7212, Inserm U944, Université Paris Diderot, Institut Universitaire d'Hématologie, Paris, France.

BACKGROUND The Gag polyproteins play distinct roles during the replication cycle of retroviruses, hijacking many cellular machineries to fulfill them. In the case of the prototype foamy virus (PFV), Gag structural proteins undergo transient nuclear trafficking after their synthesis, returning back to the cytoplasm for capsid assembly and virus egress. The functional role of this nuclear stage as well as the molecular mechanism(s) responsible for Gag nuclear export are not understood. RESULTS We have identified a leptomycin B (LMB)-sensitive nuclear export sequence (NES) within the N-terminus of PFV Gag that is absolutely required for the completion of late stages of virus replication. Point mutations of conserved residues within this motif lead to nuclear redistribution of Gag, preventing subsequent virus egress. We have shown that a NES-defective PFV Gag acts as a dominant negative mutant by sequestrating its wild-type counterpart in the nucleus. Trans-complementation experiments with the heterologous NES of HIV-1 Rev allow the cytoplasmic redistribution of FV Gag, but fail to restore infectivity. CONCLUSIONS PFV Gag-Gag interactions are finely tuned in the cytoplasm to regulate their functions, capsid assembly, and virus release. In the nucleus, we have shown Gag-Gag interactions which could be involved in the nuclear export of Gag and viral RNA. We propose that nuclear export of unspliced and partially spliced PFV RNAs relies on two complementary mechanisms, which take place successively during the replication cycle.

UI MeSH Term Description Entries
D011993 Recombinant Fusion Proteins Recombinant proteins produced by the GENETIC TRANSLATION of fused genes formed by the combination of NUCLEIC ACID REGULATORY SEQUENCES of one or more genes with the protein coding sequences of one or more genes. Fusion Proteins, Recombinant,Recombinant Chimeric Protein,Recombinant Fusion Protein,Recombinant Hybrid Protein,Chimeric Proteins, Recombinant,Hybrid Proteins, Recombinant,Recombinant Chimeric Proteins,Recombinant Hybrid Proteins,Chimeric Protein, Recombinant,Fusion Protein, Recombinant,Hybrid Protein, Recombinant,Protein, Recombinant Chimeric,Protein, Recombinant Fusion,Protein, Recombinant Hybrid,Proteins, Recombinant Chimeric,Proteins, Recombinant Fusion,Proteins, Recombinant Hybrid
D002467 Cell Nucleus Within a eukaryotic cell, a membrane-limited body which contains chromosomes and one or more nucleoli (CELL NUCLEOLUS). The nuclear membrane consists of a double unit-type membrane which is perforated by a number of pores; the outermost membrane is continuous with the ENDOPLASMIC RETICULUM. A cell may contain more than one nucleus. (From Singleton & Sainsbury, Dictionary of Microbiology and Molecular Biology, 2d ed) Cell Nuclei,Nuclei, Cell,Nucleus, Cell
D005231 Fatty Acids, Unsaturated FATTY ACIDS in which the carbon chain contains one or more double or triple carbon-carbon bonds. Fatty Acids, Polyunsaturated,Polyunsaturated Fatty Acid,Unsaturated Fatty Acid,Polyunsaturated Fatty Acids,Acid, Polyunsaturated Fatty,Acid, Unsaturated Fatty,Acids, Polyunsaturated Fatty,Acids, Unsaturated Fatty,Fatty Acid, Polyunsaturated,Fatty Acid, Unsaturated,Unsaturated Fatty Acids
D006367 HeLa Cells The first continuously cultured human malignant CELL LINE, derived from the cervical carcinoma of Henrietta Lacks. These cells are used for, among other things, VIRUS CULTIVATION and PRECLINICAL DRUG EVALUATION assays. Cell, HeLa,Cells, HeLa,HeLa Cell
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D014779 Virus Replication The process of intracellular viral multiplication, consisting of the synthesis of PROTEINS; NUCLEIC ACIDS; and sometimes LIPIDS, and their assembly into a new infectious particle. Viral Replication,Replication, Viral,Replication, Virus,Replications, Viral,Replications, Virus,Viral Replications,Virus Replications
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human
D015683 Gene Products, gag Proteins coded by the retroviral gag gene. The products are usually synthesized as protein precursors or POLYPROTEINS, which are then cleaved by viral proteases to yield the final products. Many of the final products are associated with the nucleoprotein core of the virion. gag is short for group-specific antigen. Viral gag Proteins,gag Antigen,gag Gene Product,gag Gene Products,gag Polyproteins,gag Protein,gag Viral Proteins,Gene Product, gag,Retroviral Antigen gag Protein,gag Antigens,gag Gene Related Protein,gag Polyprotein,Antigen, gag,Antigens, gag,Polyprotein, gag,Polyproteins, gag,Protein, gag,Proteins, Viral gag,Proteins, gag Viral,Viral Proteins, gag,gag Proteins, Viral
D016297 Mutagenesis, Site-Directed Genetically engineered MUTAGENESIS at a specific site in the DNA molecule that introduces a base substitution, or an insertion or deletion. Mutagenesis, Oligonucleotide-Directed,Mutagenesis, Site-Specific,Oligonucleotide-Directed Mutagenesis,Site-Directed Mutagenesis,Site-Specific Mutagenesis,Mutageneses, Oligonucleotide-Directed,Mutageneses, Site-Directed,Mutageneses, Site-Specific,Mutagenesis, Oligonucleotide Directed,Mutagenesis, Site Directed,Mutagenesis, Site Specific,Oligonucleotide Directed Mutagenesis,Oligonucleotide-Directed Mutageneses,Site Directed Mutagenesis,Site Specific Mutagenesis,Site-Directed Mutageneses,Site-Specific Mutageneses
D017354 Point Mutation A mutation caused by the substitution of one nucleotide for another. This results in the DNA molecule having a change in a single base pair. Mutation, Point,Mutations, Point,Point Mutations

Related Publications

Noémie Renault, and Joelle Tobaly-Tapiero, and Joris Paris, and Marie-Lou Giron, and Audrey Coiffic, and Philippe Roingeard, and Ali Saïb
May 2012, Journal of virology,
Noémie Renault, and Joelle Tobaly-Tapiero, and Joris Paris, and Marie-Lou Giron, and Audrey Coiffic, and Philippe Roingeard, and Ali Saïb
August 2011, Retrovirology,
Noémie Renault, and Joelle Tobaly-Tapiero, and Joris Paris, and Marie-Lou Giron, and Audrey Coiffic, and Philippe Roingeard, and Ali Saïb
September 2011, Journal of virology,
Noémie Renault, and Joelle Tobaly-Tapiero, and Joris Paris, and Marie-Lou Giron, and Audrey Coiffic, and Philippe Roingeard, and Ali Saïb
October 2005, Journal of virology,
Noémie Renault, and Joelle Tobaly-Tapiero, and Joris Paris, and Marie-Lou Giron, and Audrey Coiffic, and Philippe Roingeard, and Ali Saïb
June 2008, Molecular biology of the cell,
Noémie Renault, and Joelle Tobaly-Tapiero, and Joris Paris, and Marie-Lou Giron, and Audrey Coiffic, and Philippe Roingeard, and Ali Saïb
August 1994, Journal of virology,
Noémie Renault, and Joelle Tobaly-Tapiero, and Joris Paris, and Marie-Lou Giron, and Audrey Coiffic, and Philippe Roingeard, and Ali Saïb
June 1999, The Journal of general virology,
Noémie Renault, and Joelle Tobaly-Tapiero, and Joris Paris, and Marie-Lou Giron, and Audrey Coiffic, and Philippe Roingeard, and Ali Saïb
July 2005, Journal of virology,
Noémie Renault, and Joelle Tobaly-Tapiero, and Joris Paris, and Marie-Lou Giron, and Audrey Coiffic, and Philippe Roingeard, and Ali Saïb
April 2015, Viruses,
Noémie Renault, and Joelle Tobaly-Tapiero, and Joris Paris, and Marie-Lou Giron, and Audrey Coiffic, and Philippe Roingeard, and Ali Saïb
September 2001, Virology,
Copied contents to your clipboard!